TrialThe Lancet. Oncology2017
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Rajen Mody et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
155 papers cite itlatest 60 shown
this paperpooled ittrialcites it